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P opulation-based surveys have shown that male testosterone levels decline progressively with age 
[1].  Testosterone levels generally decrease by 0.4-2% 
per year in middle-aged and older males,  and the 
underlying mechanisms of this phenomenon remain to 
be elucidated.  Late-onset hypogonadism (LOH) indi-
cates a clinical as well as biochemical condition with 
advancing age.  The condition of LOH is characterized 
by symptoms such as general fatigue and obesity in 
addition to lowered levels of serum testosterone [2 , 3].  
LOH is a disorder that affects various functions of mul-
tiple organs,  and characteristic clinical signs for LOH 
are erectile dysfunction (ED),  loss of muscle strength,  
obesity,  osteoporosis,  anemia,  depression,  and deteri-
oration of insulin resistance [4-6].
An increased occurrence of type 2 diabetes mellitus 
(T2DM) has been shown to be,  in part,  associated with 
obesity and aging in males [7].  Of interest,  testosterone 
deficiency appears to be quite frequent in males with 
T2DM,  with a prevalence of about one-third of a male 
cohort [7].  However,  the pathogenic mechanisms 
underlying obesity and diabetes-related hypogonadism 
remain unclear.
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To determine the clinical characteristics of low androgen status in adult males with diabetes,  we retrospectively 
analyzed the medical records of patients with type 2 diabetes mellitus in whom serum free testosterone (FT) 
levels were examined for 1 year.  Among the 46 patients (56 ± 1.5 years old),  decreases in serum FT levels to 
< 8.5 pg/ml (indicating the occurrence of late-onset hypogonadism [LOH]) were detected in 18 (39%).  The per-
centages of patients with low FT levels were high in the ≥ 50 years age group (83%),  the HbA1c < 7% group 
(67%),  and the 25 ≤ BMI < 30 kg/m2 group (56%).  The serum FT levels tended to decrease age-dependently.  The 
level of HbA1c was significantly correlated with the Heinemann Aging Male Symptoms (AMS) score (R= 0.47).  
The low-FT group had decreased levels of hemoglobin.  Of note,  the serum FSH level (R= −0.32) was negatively 
correlated with the serum FT level,  whereas the serum TSH level (R= 0.36) was positively correlated with the 
serum FT level.  Collectively,  these results revealed that many diabetic males may have low FT levels and that 
the AMS score is related to the HbA1c level.  A slightly anemic condition,  thyroid dysfunction,  and obesity 
(class 1) might be involved in LOH in middle-aged diabetic males.
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In the European guidelines,  the process for the 
diagnosis of LOH is based on total testosterone levels 
[2].  However,  in a study in Japanese males,  there was 
no age-dependent decrease in total testosterone levels,  
while another study in the Japanese general population 
found that the serum free testosterone (FT) level 
decreased linearly with aging [8 , 9].  Therefore,  in 
Japan,  the examination of serum FT levels rather than 
the total testosterone levels has been recommended for 
the diagnosis of LOH in clinical settings [10].  Although 
the measurement of patients’ serum FT concentrations 
is important for the early detection and diagnosis of 
LOH status,  there have been few investigations of the 
relationships between serum FT levels and conditions of 
diabetes mellitus.
We conducted the present study to clarify the clini-
cal and laboratory characteristics of low androgen status 
in men with diabetes.  We retrospectively investigated 
the relevance of serum FT levels and the typical clinical 
features of T2DM patients who visited Okayama City 
Hospital with various symptoms.  It is of interest that we 
observed significant correlations between these subjects’ 
serum FT levels and laboratory and endocrine markers.  
Our findings may expand the utility of serum FT mea-
surement in men with diabetes.
Patients and Methods
Patients. We retrospectively analyzed the epide-
miologic records of 46 male patients with T2DM in 
whom serum FT levels were measured during the 
period from June 1,  2017 to May 31,  2018 at Okayama 
City Hospital.  Laboratory data obtained from the 46 
patients were analyzed.  We also analyzed the data of the 
28 of the 46 patients who had sufficient records of ques-
tionnaires regarding Self-Rating Depression Scale (SDS) 
scores,  a frequency scale for symptoms of gastroesoph-
ageal reflux disease (FSSG) scores,  and the Heinemann 
Aging Male Symptoms (AMS) scores to evaluate the 
relationships between the laboratory findings and the 
results of these questionnaires.
The SDS questionnaire has 20 items that include 10 
positively worded and 10 negatively worded questions 
[11].  The SDS has been recognized as a representative 
scale for clarifying the respondent’s status of depression,  
with a score of ≥ 60 indicating a depressive condition 
[12 , 13].  The FSSG score is commonly used to assess 
symptoms of gastroesophageal reflux disease (GERD) 
[14 , 15].  The FSSG questionnaire has 12 questions,  
with 7 assessing acid reflux symptoms and 5 assessing 
dysmotility-related symptoms; an FSSG score ≥ 8 is 
considered to indicate probable GERD [13-16].  The 
AMS score is designed as a self-administered scale to 
assess LOH [17].  In the scoring of the AMS,  there are 
17 items containing 3 domains for a psychological score,  
somatic score,  and sexual score,  and an AMS score ≥ 27 
indicates probable LOH [18].
Study protocol. Decisions for examining the 
patients’ serum FT concentrations were made by the 
individual physicians for clinical purposes when 
patients complained of various uncertain symptoms 
such as fatigue,  malaise,  and depressive mood suggest-
ing LOH.  Data for other biochemical parameters were 
obtained at the same time as the measurement of FT 
levels.  Blood tests were performed in cases with ade-
quate insurance coverage.  The information about 
enrollment in this retrospective study was disclosed on 
our hospital’s website and by poster notice at our hospi-
tal with an opportunity for a denial of participation,  
and we provided a contact point for participants’ opt-
out.  The protocol of this study was approved by the 
Ethical Committees of Okayama University Hospital 
(KEN-2002-021) and Okayama City Hospital (No.1-
247) and adhered to the Declaration of Helsinki and the 
Ethical Guidelines for Medical and Health Research 
Involving Human Subjects.
Analysis of clinical and laboratory parameters.
We evaluated the recorded information of the patients’ 
characteristics including age,  body mass index (BMI),  
SDS,  FSSG,  and AMS results.  The blood biochemical 
data included the following parameters: hemoglobin 
(Hb) for blood cell counts; aspartate aminotransferase 
(AST),  alanine aminotransferase (ALT),  lactate dehy-
drogenase (LDH),  creatine phosphokinase (CPK),  cre-
atinine (CRE),  and blood urea nitrogen (BUN) for liver 
and renal functions,  and hemoglobin A1c (HbA1c),  
total cholesterol (TC),  uric acid (UA),  and postpran-
dial plasma glucose (PPG).  The levels of the above- 
mentioned factors were determined using an auto- 
analyzer system at the Central Laboratory of Okayama 
City Hospital.
For endocrine data,  the levels of follicle-stimulating 
hormone (FSH),  luteinizing hormone (LH),  thyrotro-
pin (TSH),  and free thyroxine (FT4) were measured by 
a chemiluminescent enzyme immunoassay (CLIA),  and 
FT values were determined by a radioimmunoassay 
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(RIA) at LSI Medience Corp.  (Tokyo).
Statistical analyses. The data were analyzed by 
the Mann-Whitney U-test and Fisher’s exact test to 
determine significant differences between pairs of groups.  
For the evaluation of inter-relationships between the 
parameters,  we performed a linear regression analysis 
and obtained Spearman’s rank correlation coefficients.  
P-values < 0.05 were considered significant.  All statisti-
cal analyses were performed using EZR (Saitama 
Medical Center,  Jichi University,  Saitama,  Japan),  a 
graphical user interface for R (The R Foundation for 
Statistical Computing,  Vienna,  Austria,  ver. 3.5.2) [19].
Results
Patients’ characteristics and the populations with 
lowered FT. Table 1 summarizes the clinical back-
grounds of the 46 patients divided into a group with 
serum FT levels < 8.5 (n = 18; low-FT group) and a 
group with serum FT levels ≥ 8.5 (n = 28; normal-FT 
group).  There were no significant differences between 
the low- and normal-FT groups in patient characteris-
tics including age,  duration of diabetes,  body weight,  
BMI,  the number of diabetic complications (including 
neuropathy,  nephropathy,  and retinopathy),  the num-
ber of medications used (including insulin,  glucagon- 
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Table 1　 Comparison of clinical backgrounds in the low and normal groups of serum free testosterone (FT)




　Age [years] 58.5 (2.5) 53.6 (1.8) 0.219
　Duration [years] 8.1 (2.0) 7.8 (1.3) 0.883
　Body weight [kg] 81.3 (4.1) 77.3 (2.5) 0.693
　BMI [kg/m2 ] 28.6 (1.5) 27.2 (0.9) 0.761
　Diabetic complications
　　Nephropathy % (n) 56.3 (9/16) 41.7 (10/24) 0.52
　　Neuropathy % (n) 72.2 (13/18) 42.9 (12/28) 0.0716
　　Retinopathy % (n) 16.7 (3/18) 21.4 (6/28) 1
Medication
　Injection therapy
　　Insulin % (n) 27.8 (5/18) 17.9 (5/28) 0.48
　　GLP1RA % (n) 5.6 (1/18) 3.6 (1/28) 1
　Oral therapy
　　Number of OAD 2.6 (0.2) 2.8 (0.3) 0.746
　　BG % (n) 61.1 (11/18) 57.1 (16/28) 1
　　TZD % (n) 22.2 (4/18) 21.4 (6/28) 1
　　SU % (n) 22.2 (4/18) 46.4 (13/28) 0.125
　　Glinide % (n) 5.6 (1/18) 7.1 (2/28) 1
　　DPP4i % (n) 66.7 (12/18) 60.7 (17/28) 0.761
　　α GI % (n) 38.9 (7/18) 50.0 (14/28) 0.551
　　SGLT2i % (n) 38.9 (7/18) 35.7 (10/28) 1
Questionnaire
　SDS score 42.3 (2.0) 47.4 (1.5) 0.108
　FSSG score 3.9 (1.0) 3.9 (1.0) 0.731
　AMS score 31.9 (3.4) 38.5 (4.3) 0.496
Values are shown as mean (SEM) or % (n) and were statistically analyzed by the Mann-Whitney U-test and the Fisherʼs exact test.  
Significant level was set at ＊p<0.05.
BMI,  body mass index; GLP1RA,  glucagon-like peptide-1 receptor agonist; OAD,  oral antidiabetic agent; BG,  biguanide; TZD,  thiazoli-
dine; SU,  sulfonylurea; DPP4i,  dipeptidyl-peptidase IV inhibitor; αGI,  α-glucosidase inhibitor; SGLT2i,  sodium/glucose cotransporter 2 
inhibitor; SDS,  self-rating depression scale; AMS,  Heinemann aging male symptoms; FSSG,  frequency scale for the symptoms of GERD,  
and GERD,  gastroesophageal reflux disease.
like peptide-1 receptor agonist,  sulfonylurea,  glinide,  
α-glucosidase inhibitor,  biguanide,  thiazolidine,  
dipeptidyl-peptide IV inhibitor,  and sodium/glucose 
cotransporter 2 inhibitor),  or the results of question-
naires including the SDS,  FSSG and AMS.
The mean ± SEM age of the 46 male patients with 
T2DM was 56 ± 1.5 years.  Decreases of serum FT levels 
to < 8.5 pg/ml,  fulfilling the definition of LOH [10],  
were detected in 18 (39%) of the 46 patients.  As shown 
in Figure 1A,  the percentage of patients with normal FT 
was large in the 40s-to-60s age group (38/46: 83%),  
whereas the percentage of patients with low FT was 
large in the ≥ 50-years age group (15/34: 44%).  The 
mean ± SEM HbA1c level in all patients was 7.6 ± 0.21% 
(Fig. 1B).  There was a large percentage of patients with 
HbA1c levels < 8% (33/46: 72%),  and there was a large 
percentage of patients with low FT among the patients 
with HbA1c < 7%: (12/18: 67%).  The mean ± SEM 
BMI of the patients was 28 ± 0.78 kg/m2 (Fig. 1C).  There 
was a large percentage of patients with BMI levels rang-
ing from 25 to 30 (24/46: 42%),  and there was a large 
percentage of patients with low FT among the patients 
with 25 ≤ BMI < 30 (10/18: 56%).
Relationships between parameters of diabetes and 
LOH. Age-dependent changes in the levels of serum 
FT,  HbA1c,  and BMI were evaluated as shown in Fig. 2.  
The patients’ serum FT levels tended to decrease gradu-
ally in an age-dependent manner,  though the difference 
was not significant (R = −0.22,  p = 0.14; Fig. 2A).  Of 
note,  the level of HbA1c (R = −0.31,  p < 0.05; Fig. 2B) 
and the BMI (R = −0.41,  p < 0.01; Fig. 2C) both 
decreased significantly in an age-dependent manner.
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Fig. 2　 Relationships of age with serum free testosterone (FT),  HbA1c,  and BMI.  The correlations of age with (A) serum FT,  (B) 
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Fig. 1　 Patientsʼ characteristics.  Patientsʼ age (A),  HbA1c levels (B),  and body mass index (BMI) (C) are shown.  Bars in each panel 
divide the two groups based on the patientsʼ serum free testosterone (FT) levels: low FT <8.5 pg/ml and normal FT ≥8.5 pg/ml.
The relationships of HbA1c with the patients’ scores 
on the FSSG,  SDS,  and AMS were evaluated (Fig. 3).  
The level of HbA1c was significantly correlated with the 
AMS score (R = 0.47,  p < 0.05; Fig. 3C) but not with the 
FSSG score (R= −0.0085,  p= 0.97; Fig. 3A) or SDS score 
(R = 0.12,  p = 0.54; Fig. 3B).
Comparison of laboratory data in the low-FT and 
normal-FT groups. We examined and compared the 
laboratory data of the low-FT group (FT < 8.5 pg/ml) 
and normal-FT group (FT ≥ 8.5 pg/ml) (Fig. 4).  The two 
groups’ levels of hemoglobin (Hb) and liver and muscle 
enzymes (AST,  ALT,  LDH,  and CPK),  renal functions 
(BUN,  CRE,  and UA),  glucose and lipid levels (PPG,  
HbA1c,  and TC),  and endocrine data (TSH,  FT4,  
FSH,  and LH) were compared.  The Hb concentration 
was significantly lower in the low-FT group compared 
to the normal-FT group (14.6 ± 0.29 g/dl vs. 15.3 ± 0.23  
g/dl as mean ± SEM),  but the other biochemical data 
were not significantly different between the 2 groups.
Relationships between levels of endocrine parame-
ters and FT. We evaluated the relationships between 
endocrine markers and FT to determine the possible 
mechanisms underlying the onset of LOH in men with 
diabetes.  As shown in Fig. 5,  our analyses revealed that 
serum gonadotropin levels including serum levels of 
FSH (R = −0.32,  p< 0.05) were negatively correlated with 
serum FT levels compared to the serum levels of LH 
(R = −0.057; p = 0.71),  and the serum FSH levels were 
significantly related to changes in FT levels,  indicating 
that the onset of LOH is closely linked to gonadal dys-
function and a secondary increase in FSH secretion as a 
feedback mechanism.
Moreover,  the patients’ serum TSH levels (R = 0.36,  
p < 0.05) showed a significant positive correlation with 
their serum FT levels (Fig. 5C),  suggesting that a low 
level of androgen may be related to the suppression of 
TSH secretion,  i.e.,  occult hyperthyroidism,  in men 
with diabetes.
Discussion
We observed that 39% of the 46 men with diabetes 
who visited a city hospital had low levels of FT.  The 
percentages of diabetic patients with low FT levels were 
large in the ≥ 50-years age group (83%),  the HbA1c 
< 7% group (67%),  and the 25 ≤ BMI < 30 group (56%).  
The level of HbA1c was significantly correlated with the 
AMS score,  suggesting that the AMS score can be one 
of the indicators for diabetic control.  The low-FT group 
had a moderate decrease of Hb concentrations,  but 
other biochemical data including liver and renal func-
tions were not different from those in the normal-FT 
group.  Given the finding that androgen is involved in 
erythropoietic activity in males [20],  it is reasonable 
that decreased Hb was related to lowered serum FT lev-
els in the present patient series.
Of interest,  our patients’ serum FSH levels were 
negatively correlated with their FT levels (R = −0.32),  
whereas the TSH levels were positively correlated with 
FT levels (R = 0.36).  Thus,  based on the present results,  
we speculate that a slightly anemic status,  thyroid dys-
function,  and moderate obesity might be indicators of 
LOH syndrome in middle-aged diabetic males.
In our previous study [21] of patients who were sus-
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Fig. 3　 Relationships of HbA1c with the patientsʼ FSSG,  SDS and AMS scores.  The correlations of HbA1c with the (A) FSSG score,  
(B) SDS score,  and (C) AMS score were determined.  ＊p<0.05 between the indicated factors.
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Fig. 5　 Relationships of the serum FT level with endocrine factors.  The correlations of serum FT levels with (A) FSH,  (B) LH,  and (C) 




























































































































































































































Fig. 4　 Comparison of laboratory data in the low and normal serum free testosterone (FT) groups.  The patients were divided into 2 
groups based on their serum FT levels: low FT <8.5 pg/ml and normal FT ≥8.5 pg/ml.  Laboratory data for (A) Hb and the serum concen-
trations of (B) AST,  (C) ALT,  (D) LDH (E) CPK,  (F) BUN,  (G) CRE,  (H) UA,  (I) PPG,  (J) HbA1c,  (K) TC,  (L) TSH,  (M) FT4,  (N) 
FSH,  and (O) LH were analyzed by the unpaired t-test.  ＊p<0.05 between the indicated factors.
pected of having LOH and in whom serum FT levels 
were measured,  58% of the patients treated at a general 
medicine department met the criteria for the diagnosis 
of LOH syndrome.  Deficiency of testosterone affects the 
functions of not only physical but also psychological 
systems [2].  Our present findings indicate the useful-
ness of the AMS score (compared to the SDS and FSSG 
scores,  which are closely linked to psychological condi-
tions [13 , 15]) for the estimation of diabetic control in 
males with diabetes.  Underlying endocrine impairment 
related to a depressive status might also be involved in 
the deterioration of the diabetic condition.
The relevance of depressive symptoms to the preva-
lence of ED has also been reported in Japanese males 
with T2DM [22],  in whom overweight status seemed to 
be involved in both ED and declining testosterone lev-
els.  In regard to the relation between LOH and obesity,  
previous studies reported that LOH was diagnosed in 
only 0.4% of men with normal weight but in 1.6% of 
men with a BMI of 25-30 kg/m2 and in 5.2% of men 
with a BMI > 30 kg/m2,  suggesting that LOH is associ-
ated with a high BMI in males [23 , 24].  In the present 
study,  the incidence of low FT was high in the group 
with BMIs at 25-30 kg/m2,  suggesting that attention 
should be paid to obesity (class 1) in males with diabe-
tes regarding the possibility of a latent LOH condition.
Male hypogonadism is characterized by impairment 
of gonadal function with lowered circulating testoster-
one levels [25].  Hypogonadism is classified into pri-
mary and central disorders caused by hypothalamus- 
pituitary dysfunction.  The endocrine status of LOH 
cannot be simply classified into either of the specific 
categories of hypogonadism [26]; that is,  an LOH state 
is associated with gonadal dysfunction,  due mainly to 
impaired steroidogenesis and a loss of Leydig cell sensi-
tivity to gonadotropins,  which results in a decreased 
secretion of testosterone [26].  However,  the detailed 
relationships between FT and gonadotropins are not yet 
clear.  We observed a negative correlation between the 
serum levels of FT and FSH (rather than LH) in our 
present series of male diabetic patients,  suggesting that 
an LOH condition is primarily involved in the gonadal 
impairment with a secondary increase of the serum 
FSH level.
Regarding the relationship between serum FT levels 
and thyroid function [27],  several studies have shown 
an interesting role of thyroid hormones in human sex-
ual dysfunction [28] in addition to the mutual comor-
bidity of diabetes and thyroid diseases [29].  An 
increased prevalence of both hyperthyroidism and 
hypothyroidism has been reported in men with ED 
related to LOH status.  In hyperthyroid males,  it is 
known that serum total testosterone concentrations are 
often elevated as a result of increased serum levels of sex 
hormone-binding globulin (SHBG),  while their serum 
FT concentrations usually remain within the normal 
range [30].  It has also been shown that gonadotropin 
responses to gonadotropin-releasing hormone are 
enhanced in hyperthyroid males [30].
In this regard,  Zahringer et al.  [31] investigated the 
function of the hypothalamic-pituitary-gonadal axis and 
showed that both LH secretion and FSH secretion were 
increased in hyperthyroid patients.  In that study,  
gonadotropin secretion was greater in the patients with 
hyperthyroidism than in healthy subjects,  suggesting 
that hyperthyroid males are relatively resistant to 
gonadotropins,  indicating the existence of primary 
gonadal insufficiency.  This phenomenon was also indi-
cated by our present finding that the cases of patients 
with low TSH,  indicating occult hyperthyroidism,  were 
related to an LOH status that may be due to an impaired 
response to gonadotropins.
Collectively,  our present results suggest that unex-
pectedly,  many patients with diabetes have low FT lev-
els and that the AMS score tends to be related to HbA1c 
levels.  There are some study limitations to consider,  
however.  The sample size of this study was relatively 
small (n = 46),  and effects of some of the patients’ med-
ications for diabetes and lifestyle-related diseases could 
have been involved in the changes of serum FT,  
although no significant difference in the number of 
medications was detected.  In addition,  this was a ret-
rospective analysis conducted at a single city hospital.  
The results obtained herein thus cannot be interpreted 
directly.  However,  our findings indicate that a slightly 
anemic condition,  thyroid dysfunction,  and obesity 
(class 1) are clues to a latent LOH status in middle-aged 
diabetic males.
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